Maryam Yazdy: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-cell Lymphomas
Maryam Yazdy, Senior Physician on the Lymphoma team in the Division of Hematologic Malignancies 2 at CDER, FDA, shared a post on X about her new article published in Clinical Cancer Research.
“Excited to share my latest article: FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-cell Lymphomas!
Here I explore the recent FDA approval of Polatuzumab Vedotin and its impact on the treatment landscape for LBCLs.
Authors: Maryam Sarraf Yazdy, Yvette Kasamon, Wenjuan Gu, Lisa Rodriguez, Susan Jin, Vishal Bhatnagar, Nicholas Richardson, Marc Theoret, Richard Pazdur, Nicole Gormley.
Maryam S. Yazdy is a Senior Physician on the Lymphoma team in the Division of Hematologic Malignancies 2 at the Center for Drug Evaluation and Research (CDER), FDA. She previously served as a Medical Officer in the same division. Prior to joining the FDA, she was a Lymphoma and CLL oncologist at Georgetown University’s Lombardi Comprehensive Cancer Center.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023